Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes

Gingival overgrowth is a side effect of certain medications, including calcium channel blockers, cyclosporin A, and phenytoin. Phenytoin-induced gingival overgrowth is fibrotic. Lysyl oxidases are extracellular enzymes that are required for biosynthetic cross-linking of collagens, and members of thi...

Full description

Bibliographic Details
Main Authors: Findlay, A.D (Author), Kantarci, A. (Author), Mahjour, F. (Author), Mously, E.A (Author), Saxena, D. (Author), Trackman, P.C (Author)
Format: Article
Language:English
Published: SAGE Publications Inc. 2018
Subjects:
Online Access:View Fulltext in Publisher
LEADER 02950nam a2200589Ia 4500
001 10.1177-0022034518775971
008 220706s2018 CNT 000 0 und d
020 |a 00220345 (ISSN) 
245 1 0 |a Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative Processes 
260 0 |b SAGE Publications Inc.  |c 2018 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1177/0022034518775971 
520 3 |a Gingival overgrowth is a side effect of certain medications, including calcium channel blockers, cyclosporin A, and phenytoin. Phenytoin-induced gingival overgrowth is fibrotic. Lysyl oxidases are extracellular enzymes that are required for biosynthetic cross-linking of collagens, and members of this enzyme family are upregulated in fibrosis. Previous studies in humans and in a mouse model of phenytoin-induced gingival overgrowth have shown that LOXL2 is elevated in the epithelium and connective tissue in gingival overgrowth tissues and not in normal tissues. Here, using a novel LOXL2 isoform-selective inhibitor and knockdown studies in loss- and gain-of-function studies, we investigated roles for LOXL2 in promoting cultures of human gingival fibroblasts to proliferate and to accumulate collagen. Data indicate that LOXL2 stimulates gingival fibroblast proliferation, likely by a platelet-derived growth factor B receptor-mediated mechanism. Moreover, collagen accumulation was stimulated by LOXL2 enzyme and inhibited by LOXL2 inhibitor or gene knockdown. These studies suggest that LOXL2 could serve as a potential therapeutic target to address oral fibrotic conditions. © International & American Associations for Dental Research 2018. 
650 0 4 |a adult 
650 0 4 |a Adult 
650 0 4 |a Amino Acid Oxidoreductases 
650 0 4 |a Blotting, Western 
650 0 4 |a cell biology 
650 0 4 |a cell culture 
650 0 4 |a cell proliferation 
650 0 4 |a Cell Proliferation 
650 0 4 |a Cells, Cultured 
650 0 4 |a collagen 
650 0 4 |a Collagen 
650 0 4 |a extracellular matrix 
650 0 4 |a female 
650 0 4 |a Female 
650 0 4 |a fibroblast 
650 0 4 |a fibroblasts 
650 0 4 |a Fibroblasts 
650 0 4 |a gene knockdown 
650 0 4 |a Gene Knockdown Techniques 
650 0 4 |a gingiva 
650 0 4 |a Gingiva 
650 0 4 |a growth, development and aging 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a LOXL2 protein, human 
650 0 4 |a matrix biology 
650 0 4 |a metabolism 
650 0 4 |a oxidoreductase 
650 0 4 |a physiology 
650 0 4 |a platelet derived growth factor beta receptor 
650 0 4 |a Receptor, Platelet-Derived Growth Factor beta 
650 0 4 |a receptors 
650 0 4 |a Western blotting 
700 1 |a Findlay, A.D.  |e author 
700 1 |a Kantarci, A.  |e author 
700 1 |a Mahjour, F.  |e author 
700 1 |a Mously, E.A.  |e author 
700 1 |a Saxena, D.  |e author 
700 1 |a Trackman, P.C.  |e author 
773 |t Journal of Dental Research